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Abstract
Development of an automated method for CSF bilirubin measurement

Subarachnoid haemorrhage (SAH) is a potentially fatal condition which can be difficult
to accurately diagnose. Patients often present with a second bleed which can be more
damaging than the initial bleed. Diagnosis of SAH centres on computed tomography
(CT) scans. However, 2% of patients positive for SAH will present as negative on CT
scans. It is recommended that these patients have lumbar puncture and the CSF is
analysed for bilirubin. The presence of bilirubin is suggestive of SAH.
Spectrophotometric scanning involves expensive equipment which is often not available
in routine settings. A need exists for a robust, inexpensive, automated method for CSF
bilirubin measurement.
I’his project adapted the serum bilirubin method in routine use in Biochemistry Cork
University Hospital (CUH ), in order to achieve bilirubin measurement at levels in
nmol/l. This level of sensitivity would be required for CSF bilirubin measurement. The
adapted method was found to be precise, linear, and sensitive at low levels. The method
was compared to the gold-standard spectrophotometric method and found to correlate
well. The new method is promising as a screening method to correctly identify:
1) Patients negative for SAH who require no further intervention
2) Patients who may be positive for SAH and should proceed for spectrophotometric
scanning.
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Section 1
Introduction

1.1 Subarachnoid Haemorrhage
Subarachnoid haemorrhage (SAH) is spontaneous arterial bleeding into the subarachnoid
space. This occurs as a result of trauma to the head or, more commonly, due to a cerebral
aneurysm. Between 1 and 4 % of patients presenting to emergency medicine departments
with headache have a diagnosis of subarachnoid haemorrhage '. Up to 50% of SAH
cases are fatal . The remainder of cases may result in significant neurological damage.
Patients in whom the initial diagnosis of SAH is missed often bleed again, which may
frequently result in more severe outcomes for the patient. Early detection of SAH is
therefore crucial, in order to allow definitive surgical treatments to prevent further
complications, thereby improving patient outcomes
Intracranial aneurysms develop in the course of life. Saccular aneurysms occur at sites of
arterial branching, most commonly at the base of the brain

Only a small percentage of

these aneurysms rupture. Risk factors for aneurysm can include smoking, hypertension,
excessive alcohol consumption and genetic factors. Although the incidence of SAH
increases with age, 50% of cases occur in patients <50 years of age

It may therefore

result in significant loss of productive years in this population group.

1.2 Clinical presentation
The most common presentation of SAH patients in emergency medicine departments is
with a characteristic rapid onset of a “thunderclap headache”. This is typically described
as the most severe headache the patient has ever had and is generally a diffuse headache.
Onset may occur within a few seconds and this sudden onset is the characteristic feature
Transient loss of consciousness or weakness is frequently present, and may be followed
by vomiting.

Physical examination of the patient on admittance may reveal retinal haemorrhages
which may indicate site of aneurysm, restlessness and diminished consciousness, neck
stiffness and focal neurological signs

However, the absence of these symptoms on

physical examination may mean that the diagnosis is missed, resulting in an incorrect
diagnosis for those patients who have the greatest likelihood of benefiting from
interventions.
The most common complications of SAH are rebleeding, cerebral vasospasms,
hydrocephalus and myocardial ischaemia. Detecting and treating initial bleeds to prevent
development of complications is critical due to the high rate of mortality from rebleeding
and cerebral vasospasms.
All patients, therefore, presenting with thunderclap headache should be investigated for
SAH.

1.3 Diagnosis
The first diagnostic test for SAH should be a non-contrast computerized tomography
(CT) scan. This is currently the cornerstone of SAH diagnosis and provides a 3-D image
of the area of interest. CT scans can be highly reliable prognostic indicators of the clinical
course, particularly in predicting the development of vasospasm. Non-contrast CT is
preferred as contrast may obscure the location of the SAH. CT scans will be positive in
98% of patients with SAH presenting within 12 hours of bleed

However, positivity falls

to approximately 50% in patients who present after one week. Magnetic resonance
imaging (MRl) may be useful in patients who present at a later stage but CT scans
currently remain the method of choice due to lower cost, wider availability and easier
interpretation of results '.

Patients with positive CT scans will usually be sent for cerebral angiography. Cerebral
angiography has the advantage over MRl of allowing interventions to be performed while
also providing visual representation of cerebral blood vessels. The most effective
treatment for a patient with ruptured cerebral aneurysm is microsurgical clipping of the
aneurysm as soon as possible after the initial haemorrhage. Once adequately clipped, the
risk of re-haemorrhage is avoided.
For patients with suspected SAH who have negative CT scans, there is a need for another
procedure to assist in correct diagnosis. This ensures that those patients who have SAH
are identified and can be referred for cerebral angiography. Also, those patients who do
not have SAH will not be subjected to a procedure which is invasive, expensive and has a
definite risk of morbidity and mortality

Negative CT scan results in patients who have had SAH may occur if

a) The scan is performed >12 hours post event
b) Expert neuroradiologists are not available to interpret the scans
c) Patient has a very small haemorrhage.

Therefore, in patients wliose clinical presentation suggests SAH and whose CT scan is
negative, it is recommended that lumbar puncture should be performed ’ and the CSF
examined for the presence of bilirubin by spectrophotometry.

1.4 Bilirubin
Bilirubin is an orange-yellow pigment, derived from senescent red blood cells.
Bilirubin is produced from the catabolism of heme by a microsomal heme oxygenase.
The first step in the degradation of the heme group to bilirubin is the cleavage of its amethane bridge by heme oxygenase to form the green pigment biliverdin. Bilirubin is
rendered soluble in plasma by protein-binding, mainly to albumin. Bilirubin complexed
to albumin is transported to the liver, where it is made more soluble by the attachment of
glucuronates. The conjugate of bilirubin and two glucuronates is excreted into bile.

Fe2+ + CO +

heme

Figure 1; Conversion of heme to biliverdin by heme oxygenase

biliverdin

This is subsequently reduced to bilirubin by the reduced form of nicotinamide adenine
dinucleotide phosphate (NADPH)-dependent, cytosolic enzyme biliverdin reductase

Figure 2; Conversion of biliverdin to bilirubin by bilirubin reductase

1.5 CSF Bilirubin
Subarachnoid haemorrhage releases red blood cells into the CSF, where they undergo
lysis, releasing oxyhaemoglobin, which may be detected in the CSF 2-12 hours post
bleed

The enzyme haem oxidase, which is found in macrophages, converts the
.1'^.

oxyhaemoglobin to bilirubin and sometimes to methaemoglobin

This may be detected

up to 2 weeks post bleed. Both oxyhaemoglobin and methaemoglobin may arise due to in
vitro factors. Bilirubin arises solely from an in vivo mechanism.
The presence of pigments in CSF alter its appearance, with oxyhaemoglobin resulting in
a red or orange appearance, and bilirubin resulting m a yellow colour

. The presence of

this xanthochromia was traditionally used by laboratories to visually assess CSF for the
presence of bilirubin, but this approach has since been shown to be subjective and non
specific

Despite this it remains a practice in many hospitals. Twenty-five hospitals

from the region of Northern Ireland, Scotland, Wales and England affirmed visually
scanning CSF specimens, in response to an audit of cerebrospinal fluid testing conducted
by NEQAS in 2007

Results of the visual inspection were used in some cases to

determine which samples should be investigated for the presence of bilirubin by more
specific methods.
The current method of choice for investigation of suspected SAH in CT- negative
patients is lumbar puncture and detection of CSF bilirubin by spectrophotometry. CSF
spectrophotometry to detect haem pigments was introduced in 1955'^ and has been
developed in subsequent decades, resulting in present day sophisticated instruments
capable of precise detection and quantification of pigments. Evaluation of
spectrophotometric spectra should be conducted with fit-for-purpose techniques'^.

Correctly interpreting CSF findings involves distinguishing traumatic taps from true
hemorrhage. Traumatic taps occur in up to 20% of lumbar punctures , introducing red
blood cells (RBCs) to the CSF.
CSF bilirubin spectrophotometry is useful in identifying SAH patients presenting several
days after haemorrhage, and also to distinguish between SAH and traumatic lumbar
puncture. The presence of bilirubin pigment, determined by CSF spectrophotometry, has
been shown to rule out a purely traumatic origin of RBCs in CSF obtained by lumbar
puncture
The presence of both oxyhaemoglobin and bilirubin should be detected, as one or both of
these pigments may contribute to xanthochromia after SAH. Most positive cases of SAH
will result in the presence of both oxyhaemoglobin and bilirubin peaks. Oxyhaemoglobin
may occur on its own if the CSF sample is taken a very short time after a bleed. Although
this is unusual, it is an important issue to be aware of, as the absorbance of the
oxyhaemoglobin peak may be great enough to obscure a small but significant amount of
bilirubin present at this stage*" . Bilirubin occurring on its own may be a possibility
several days post bleed.
Methaemoglobin occurring alone is a very unusual finding and may be related to the
artefactual conversion of oxyhaemoglobin. Recent studies suggest the possibility that
high concentrations of iodine, often used as a skin disinfectant when performing lumbar
punctures, may have a role in in vitro methaemoglobin formation
An increase in CSF bilirubin is the key finding, which supports the occurrence of SAH,
although it is not specific for this.

National guidelines for laboratory analysis of CSF by spectrophotometry in SAH were
published by NEQAS in 2003

and revised in 2008^.

These guidelines offer important recommendations regarding specimen requirements and
transport, specimen handling, reporting and interpretation.

One important recommendation from these guidelines is that a simultaneous sample
should be taken for serum bilirubin and total protein measurement. This is essential as a
high serum bilirubin level can result in a “spillover” of bilirubin into the CSF. Patients
with hyperbilirubinaemia will usually have been identified prior to tap, e.g.: through
jaundice or liver function tests. Measurement of serum bilirubin identifies patients with
hyperbiliurbinaemia. An extremely high CSF protein level may suggest increased
permeability of the blood-brain barrier and enhanced movement of serum free bilirubin
into the CSF. Correction for high serum bilirubin or high total protein can be useful in
excluding false positive results in CSF spectrophotometry.
The predicted absorbance (PA) of a CSF at 476 nm due to bilirubin can be calculated
according to the following equation "" :

CSF total protein (g/L)
PA

=

Serum total protein (g/L) x serum bilirubin (umol/1) x 0.042AU

1.6 Automated Methods
Although the recommended method for bilirubin detection in CSF is spectrophotometric
scanning, this method is often not routinely available in hospital laboratories, particularly
in smaller centres, primarily due to the cost of equipment. Attempts have been made
therefore to develop other methods for CSF bilirubin detection and measurement. These
have focused mainly on adapting automated methods for serum bilirubin measurement, to
enable them to detect bilirubin at the much lower levels which would be expected in CSF.
The advantage of developing these methods could lie in their use as a screening method,
to determine those patients who should go for further investigation by spectrophotometric
scanning, and those who have no evidence of CSF bilirubin and require no further testing.
The ultimate goal of testing is to correctly identify those patients who will benefit from
medical interventions, and to eliminate the necessity of these expensive and invasive
diagnostic interventions in patients who do not require them. Development of a simple,
robust, automated method which correlates well with the gold-standard
spectrophotometric method would be of great benefit for routine laboratories to assist in
clinical diagnosis of SAD.

1.7 Bilirubin measurement
Bilirubin can be measured by a number of different methods. The most commonly used
chemical methods are based on the diazo reaction. In this reaction, diazotized sulfanilic
acid (the diazo reagent) reacts with bilirubin to produce two azodipyrroles which are
reddish-purple at neutral pH and blue at low or high pH values.
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In 1938, Jendrassik and Grof described a diazo method

later modified by Doumas et

aP^, which gives results for serum bilirubin measurement that are reliable and
reproducible. This method uses caffeine benzoate as the accelerator. The mechanism of
action of caffeine benzoate remains unclear but it is thought to displace the unconjugated
bilirubin from the albumin, and make the unconjugated bilirubin more water soluble by
the disruption of the internal hydrogen bonds. This method has acceptable transferability
among laboratories and is the method of choice in many routine laboratories.

HPLC methods have also been developed that allow separation and quantification of
bilirubin fractions. HPIX can be helpful in determining the nature of bilirubin species
occurring naturally in blood, or during phototherapy " . However, HPLC techniques are
labour intensive and require specialized equipment.
Enzymatic methods for bilirubin measurement are based on oxidation of bilirubin with
bilirubin oxidase to biliverdin with molecular oxygen

. Biliverdin is further oxidized to

purple and then to colourless products. The decrease in absorbance, at 425 or 460nm, is
proportional to the concentration of bilirubin.
In 1993, O’Leary et al described a method for measuring bilirubin using potassium
ferricyanide

In the presence of caffeine/benzoate, bilirubin is oxidized to biliverdin,

and the absorbance change at 480nm is measured. The O’Leary bilirubin method is the
method currently used in the Biochemistry laboratory in Cork University Hospital for
serum bilirubin measurement. It is run as an automated method on an Olympus chemistry
analyzer.

1.8 Automated CSF bilirubin measurement

A number of routine, automated methods for serum bilirubin measurement have been
adapted for CSF bilirubin detection and measurement. All methods involve an increase in
the sample volume used in the assay in order to increase sensitivity.
These include:
a) A method based on the Jendrassik-Grof principle, described by Doumas et al, modified
by Chan et al, on an Abbott Aeroset analyzer" . This method was found to be an easy and
robust test and could be recommended for use in a stat environment to screen patients for
increased NBA as defined by spectrophotometric scanning.
b) A method based on a diazo method for bilirubin measurement, on a Dade-Behring
.

•

'^7

Dimension analyzer" . This method was again simple and robust and was recommended
as a suitable screening assay, or even as suitable to replace spectrophotometry.
c) A method based on a variation of a diazo method using a diazonium ion, on a Roche
Modular <P> analyzer

The Modular CSF bilirubin assay was found to easily identify

normal results. Samples with raised bilirubin or haemoglobin were subjected to
spectrophotometric scanning.
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1.9 Objectives of this project

1.) To modify and optimise the O’Leary method for serum bilirubin measurement on
an Olympus AU400 chemistry analyser in order to detect the low levels of
bilirubin expected in the CSF of SAH patients.

2.) To validate the method for CSF bilirubin measurement
This includes examining
a) Limit of detection
b) Within run precision
c) Between run precision
d) Linearity
e) Accuracy
0 Recovery

3.) To investigate interference of haemoglobin on the method

4.) To compare the results obtained by the automated AU400 method to results
obtained by the recommended gold-standard spectrophotometry method

Section 2
Materials and Methods
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2.1 Materials
2.1.1 Chemicals:

2.1.1.1 O’Leary total bilirubin reagents in use on Olympus AU40Q
Reagent 1 contains sodium benzoate, caffeine, EDTA and TRIS
Reagent 2 contains potassium ferricyanide and sodium chloride.

2.1

■ 1.2 Distilled Water

All water used was reagent grade produced by the ELGA PURELAB Option R system
The water purification system purifies the water using reverse osmosis (R/0) with a pre
treatment cartridge to remove any large particles suspended in the water. The purihcation
system also has a water polisher after the reverse osmosis purification step.

2.1.2 Instrumentation:
Olympus:

400 Automated Chemistry Analyser
Olympus Diagnostics

Water Purification:

ELGA PURELAB Option R
Vivendi Water Systems

Spectrophotometer:

Camspec M550 Double Beam Scanning UV/Vis
Spectrophotometer
Spectronic Analytical Instruments
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2.1.3 Clinical Samples:

Samples received in the Biochemistry laboratory for routine biochemical analysis and
which were due to be discarded were stored at -20°C in the dark after analysis. Adult
serum samples with low to normal Total Bilirubin (TB) values were pooled. CSF samples
with zero bilirubin values were pooled and spiked with bilirubin calibrator. Full
confidentiality was maintained at all times and only samples that were not required by the
biochemistry laboratory were used. Paediatric samples were not used.

2.1.4 Materials for haemoglobin interference:

Samples with a low to normal bilirubin level were separated and the cells were removed.
These cells were frozen and then thawed to release the haemoglobin from the cells and
the haemolysate was centrifuged to remove any debris. The haemoglobin level was
quantified on a Sysmex XE2100 haematology analyzer and varying amounts of this
haemoglobin stock solution were added to a bilirubin pool.

Haemoglobin calibrator in use in haematology laboratory in CUH was obtained as a
second source of haemoglobin. This had a defined value of 11.5 g/1 Hb.
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2,1.5 Calibration and quality control material:

Calibrator materials used were
a) Seronorm Bilirubin Calibrator. This is a lyophilized human serum calibrator
intended to be used with the O’Leary Total Bilirubin reagent for the quantitative
determination of total bilirubin on the Olympus analysers. The calibrator was
diluted to values appropriate for detection of low levels of bilirubin in CSF.

b) Olympus system master calibrator for total chemistry analyses.

Both calibrators were stored in the dark at 4°C. The Sernorm bilirubin calibrator was
reconstituted with 1ml distilled water prior to use,
fhe calibrators were diluted with distilled water to give values of between 0 and
300umol/l bilirubin. Calibrators were also used to create test samples of values across
the range of interest.

Quality control materials used were:
a) Internal QC material in use in Biochemistry, Cork University Hospital, i.e.:
Beckman Triad NYSSPATH Comprehensive Custom Unassayed Chemistry
Control Serum. Triad 2 and Triad 3.
b) A patient pool of serum was diluted with distilled water to give values of 155 and
450 nmol/1 bilirubin. These were divided into aliquots of 300ul which were stored
in the dark at -20°C. The aliquots were thawed and mixed well prior to use.

16

2.2 Methods

2.2.1 O’Leary method for total bilirubin
Potassium ferricyanide oxidizes bilirubin to biliverdin and this reaction may be
monitored spectrophotometrically at 480nm to quantify the amount of bilirubin in a
samplefO'Leary Niall, 1993).

Potassium ferricyanide

Biliverdin

Bilirubin
480nm

(Green Colour)

Figure 3: Representation of the oxidation of bilirubin to biliverdin by the action of
potassium ferricyanide

Principle of O’Leary method for bilirubin measurement on AU400 chemistry analyser:
Bilirubin in serum or plasma when mixed with Reagent 1 absorbs light at 450-470nm
with secondary readings at 600 to 660 nm. The addition of Reagent 2 oxidises the
bilirubin to biliverdin by the presence of ferricyanide ions. The difference in absorption is
measured using the analyser’s self-blanking facility.
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Parameters on the Olympus 400 used for Total Bilirubin measurement are as follows:

Sample:

R

ul

Dilution

0

Reagents:

SO

ul

Dilution

200

SO

ul

Dilution

0

Wavelength:

Primary

Secondary

Measuring Point 1 (secs): First

Last

Method:

Measuring Point 2(secs): First

q

27

Last

These parameters were varied in an attempt to optimise this method for CSF Bilirubin
measurement.
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2.2.2 Spectrophotometry

A zero order spectrophotometrie scan is performed between 350nrn and 600nm using a
recording spectrophotometer and a 1cm light path. An initial full-scale deflection (FSD)
of 0.1 absorbance unit (AU) is used. The scan is inspected for the presence of the
following haem pigments:

Oxyhaemoglobin: absorbance maximum between 410 and 418nm
Bilirubin: either a broad peak in the range 450 to 460nm or a shoulder adjacent to an
oxyhaemoglobin peak if present
Methaemoglobin: the rarest pigment and if present usually manifests as a broader peak
than oxyhaemoglobin occurring between 403 and 410nm
Analysis of spectrophotometrie scan is performed using the computer program on the
computer attached to the spectrophotometer

19

2.2.3. Optimisation of the parameters

The defined parameters for the O’Leary total bilirubin assay on the Olympus 400
chemistry analyzer were changed and examined.
These changes included:
a) Increasing the sample volume used in the assay
b) Decreasing the reagent volume used
c) Using different calibrators when examining the parameters
With each change, the assay was calibrated and a straight line obtained before testing.
Using a calibrator of known value, or using a patient pool of known value, dilutions were
prepared to give test samples across a range of interest. These were run against the
parameters under investigation.

2.2.4. Evaluation and Validation of the Assay
The final parameters chosen for the measurement of CSF bilirubin were as follows:
Sample:
Reagents:

Wavelength:

Volume

SO

R1 Volume

2S

R2 Volum^

2S

Primary

Method:

ul

ul

ul

480
FND

Measuring Point 1 (secs): First

Last

27

Measuring Point 2(secs): First

Last

10
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Validation of the assay was performed using these parameters.

2.2.4.1 Within run (intra) precision

Precision studies were formed using the Olympus system master calibrator. The
calibrator was diluted to give bilirubin values of 50nmol/l, lOOnmol/1 and 200nmol/l.
These values were run 20 times each. The mean concentration, standard deviation (S.D.)
and coefficient of variation (C.V.%) was calculated for each of the three levels.

2.2.4.2 Between run (inter) precision
Using the Olympus system master calibrator, the calibrator was diluted to give bilirubin
values of 155 nmol/1 and 450 nmol/1. Aliquots of these levels were stored in the dark at
-20°C. Aliquots, which were thawed and mixed well prior to use, were run several times
over the course of a day, and also run on different days over a period of four weeks. The
mean concentration, standard deviation (S.D.) and coefficient of variation (C.V.%) was
calculated for each of the three levels.

2.2.4.3 Limit of Detection
The sensitivity or limit of detection of the assay was expressed as the least amount
measurable that could be significantly distinguished from zero.
Using distilled water and saline, 20 replicates of each was analysed for bilirubin. The
mean concentration and standard deviation of each was obtained. The limit of detection
was calculated as zero plus 2.5 times the standard deviation of the twenty results.
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2,2.4.4 Linearity
Using a patient pool of serum with a known value of total bilirubin, a test pool of value of
1000 nmol/1 bilirubin was created by dilution with saline. The pool was further diluted to
give values of between 0 and 1000 nmol/1 bilirubin. These test samples were analysed
using the chosen parameters. The results actually obtained were plotted against the
expected values, and the graph was observed for linearity. The correlation coefficient was
calculated.

2.2.4.5 Hb Interference
Increasing amounts of haemoglobin (Hb) were added to two patient pools and analysed
for bilirubin using the CSF parameters. The samples were also assayed for haemoglobin
using the Sysmex XE2100 haematology analyzer. Hb was obtained from two sources i.e.
(i) from patient red blood cells and (ii) from a defined Hb calibrator.

22

2.2.5 Correlation between 400 and Camspec

a) serum based matrix
A patient serum pool of known total bilirubin value was diluted in saline to give values
between 0 and 500 nmol/1 bilirubin. These test samples were run on the AU400 chemistry
analyzer, using the CSF bilirubin parameters. The same samples were run on the
Camspec M550 spectrophotometer. The results of both methods were compared, and
statistical analysis was performed.

b) CSF based matrix
A patient CSF pool of zero umol/1 bilirubin was spiked with a known amount of bilirubin
obtained from a diluted serum pool. The pool was diluted to give values of between 0 and
400 nmol/1 bilirubin. These test samples were run on the AU400 chemistry analyzer,
using the CSF bilirubin parameters. The same samples were run on the Camspec M550
spectrophotometer. The results of both methods were compared, and statistical analysis
was performed.

2.2.6 Statistical Analysis:
Statistical analysis of the data was accomplished using the Analyse -it software program
(Analyse-it, 1997-2008)

Section 3
Results
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Section 1
3.1 Optimisation of parameters
To investigate the optimisation of parameters, the defined parameters for the
measurement of serum total bilirubin on the Olympus AU400 chemistry analyzer were
adjusted and examined. Two different calibrators were used, i.e.: the seronorm total
bilirubin calibrator and the Olympus system master calibrator. Various changes to the
parameters were investigated, in an attempt to achieve sensitivity at nmol/1 levels.
3.1.1. Seronorm Bilirubin Calibrator
The initial investigations were carried out using the seronorm bilirubin calibrator. This
calibrator has a defined bilirubin value of 320umol/l. dTis was diluted in distilled water
to give values of 0 to lOOOnmol/l.

Figure 3: Absorbance changes observed using seronorm bilirubin calibrator
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Control materials Triad 2 and Triad 3, with defined bilirubin values of 89umol/l and 123
umol/1 respectively were similarly diluted to values in nmol/1 levels. These were used as
initial test samples.
3.1.1.1 Increasing sample volume
The sample volume was increased from Sul to 50ul, the maximum volume allowed on the
instrument. The assay was calibrated using values made up from dilutions of the
calibrator and test samples were run.
Parameters: Sample Volume = 50ul
Reagent 1 = 50ul in 200ul diluent
Reagent 2 = 50ul in Oul diluent

Figure 4: Results obtained after increase in sample volume.
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3.1.1.2. Reducing Reagent 1 Volume
As the instrument does not permit sample volume to be increased above 50ul, the volume
of Reagent 1 is reduced in a bid to increase sensitivity of the assay.
Parameters: Sample Volume = 50ul
Reagent 1 = 50ul in 150ul diluent
Reagent 2 = 50ul in Oul diluent

Figure 5: Results using maximum sample volume and reduced volume of Reagent 1.
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Reagent 1 volume was further reduced and investigated using test samples made up from
both calibrator material and from QC material. Two different sources are used to create
test samples in order to eliminate the possibility of erroneous results due to matrix
differences
Parameters: Sample Volume = 50ul
Reagent 1 = 50ul in 1 lOul diluent
Reagent 2 = 50ul in Oul diluent

Figure 6: Further reduction in reagent volume. Investigated using test samples made up
from seronorm bilirubin calibrator.

27
3.1.1.3. Investigation of parameters using samples made from QC material

Test Samples from QC
material

Figure 7: Further reduction in reagent volume. Investigated using test samples made up
from QC material.

Values obtained using test samples made up from calibrator material are more
comparable than values from test samples made up from QC material, as would be
expected. An extended investigation was carried out using test samples across a wider
range, made up from QC material.
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Parameters: Sample Volume = 50ul
Reagent 1 = 50ul in 120ul diluent
Reagent 2 = 50ul in Oul diluent

Figure 8: Investigation of QC test samples across a wider range.
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3.1.1.4. Investiaation of parameters using test samples created from a patient pool of
serum.
Test samples made up from QC material performed particularly poorly at lower ranges.
This may be due to the high level of dilution at these ranges. QC material may therefore
be unreliable to examine these lower levels. Another matrix is chosen to further
investigate these parameters. A patient pool of serum was obtained with a known serum
total bilirubin level. This was diluted with distilled water to give test samples in the range
ofO to 1000 nmol/1. Assay was calibrated using a 7 point calibration curve with values
from 0 to lOOOnmol/1.
Parameters: Sample Volume = 50ul
Reagent 1 = 50ul in 135ul diluent
Reagent 2 = 50ul in Oul diluent
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3.1.1,5. Investigation of parameters using calibration curve of 0 to 300 nmol/1
As very low levels of bilirubin would be expected in CSF, even post ictus, the lower
range and discernible differences here are of particular interest from a clinical viewpoint.
Therefore, the assay was recalibrated using a 7 point calibration curve with values from 0
to 300 nmol/1. This was investigated using test samples made up from calibrator material,
and also test samples made up from a patient pool.
Parameters: Sample Volume = 50ul
Reagent 1 = 50ul in 135ul diluent
Reagent 2 = 50ul in Oul diluent

Test Samples from Calibrator
Material

Expected Bilirubin Value (nmol/l)

Figure 10: Investigation of 0 to 300 nmol/l cal curve, using samples made from calibrator
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Figure 1 1: Investigation of 0 to 300 nmol/1 cal curve, using samples made from patient
serum pool.

Results obtained by these parameters are very imprecise. Lots of random errors may be
observed. There is difficulty distinguishing between values close to each other,
particularly at lower levels and around the area of clinical interest. These parameters are
not suitable for routine laboratory use.
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3,1.1.6 Precision checks with parameters
3.1.1.6.1. Inter run precision
20 replicates of three values were run under assay conditions. Values chosen were
50nmol/l, 150nmol/l and 450 nmol/1. Test samples were made up from the seronorm
bilirubin calibrator. Results were recorded and data was analysed.
n = 20

SOnmol/l

150n mol/1

450nmol/l

Mean

20.2

85.2

261.8

S.D.

11.2

9.3

10.9

CV%

55.3%

1 1%

4.2%

Table 1: Statistical Analysis of inter run precision studies
3.1.1.6.2. Intra run precision
20 replicates of three values were run under assay conditions. Values chosen were
50nmol/l, 150nmol/l and 380 nmol/1. Test samples were made up from the seronorm
bilirubin calibrator. Results were recorded and data was analysed.
n= 15

50nmol/l

ISOnmol/l

380nmol/l

Mean

39.3

120.0

250.5

S.D.

33.0

38.2

93.2

cv%

84%

31.65

37.2%

Table 2: Statistical Analysis of intra run precision studies.
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3.1.2. Olympus system master calibrator
The absorbance value changes of the seronorm bilirubin calibrator were very small,
which could account for the imprecision of the assay. Therefore, a different calibrator
was used, i.e.: the Olympus system master calibrator. This calibrator has a defined value
of 58.9umol/l bilirubin. This calibrator was diluted in distilled water to give a 7 point
calibration curve, 0, 50, 100, 150, 200, 250, 300 nmol/1.

Figure 12: Absorbance changes of Olympus system calibrator and of seronorm calibrator
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The reagent volumes used were decreased in bid to further increase sensitivity of the
assay. Samples were created from a patient serum pool to give test samples of values
between 0 and 300 nmol/1.

Parameters: Sample Volume = 50ul
Reagent 1 = 25ul in lOOul diluent
Reagent 2 = 25ul in Oul diluent

Figure 13: Investigation ofO to 300 nmol/I calibration curve using Olympus calibrator.
Test samples created using dilutions of patient serum pool.
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Section 2

3.2 Validation of Assay

Parameters: Sample Volume = 50ul
Reagent 1 = 25ul in lOOul diluent
Reagent 2 = 25ul in Oul diluent

I'he above parameters and the Olympus system calibrator are to be used as the optimal
parameters for measurement of CSF bilirubin by the O’Leary method on the AU400
chemistry analyzer. The absorbance changes observed using the Olympus system master
calibrator were greater than those observed using the seronorm calibrator. Results of test
samples made up from patent pool obtained using these assay conditions correlated
reasonably well with expected values. Few random errors were observed and differences
between values, even values close together, could be clearly observed. Therefore, the
assay will be validated using these conditions.
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3.2.1 Precision Studies
3.2.1.1. Inter run precision
20 replicates of three values were run under optimal assay conditions. Values chosen
were 50nmol/l, 100 nmol/1 and 200 nmol/1. Data was recorded and analysed.
n = 20

SOnmol/l

lOOnmol/1

200nmol/l

Mean

58.007

107.508

212.577

S.D.

6.567

8.697

9.166

cv%

11.3 %

8.1 %

4%

I'able 3: Statistical Analysis of inter run precision studies

3.2.1.2. Intra run precision
50 replicates of two values were run under optimal assay conditions. Values chosen
were 155 nmol/1 and 450 nmol/1. Data was recorded and analysed.

n = 50

155 nmol/l

450 nmol/l

Mean

138.851

423.49

S.D.

17.7

46.737

CV%

12.7%

11.0%

Table 4: Statistical Analysis of intra run precision studies
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3.2.2 Limit of detection

n = 20

Distilled Water (nmol/l)

Saline (nmol/l)

Mean

21.086

17.174

S.D.

11.03

12.658

Limit of Detection

43.146

42.474

(Mean + 2 S.D.)

Table 5: Statistical Analysis of limit of detection studies
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3.2.3 Linearity
A patient pool of known serum bilirubin value was diluted with distilled water to give 5
test samples of values between 0 and 1000 nmol/l. These were run using optimal
parameters.

Scatter Plot with Ft

Identity

Linear fit

(-30.64 + 1.05X)

Figure 14: Graph of linearity studies.

A correlation coefficient of 0.99 was observed for the linearity
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Section 3

3.3.1 Haemoglobin interference

Haemoglobin interference (Hb source = RBC's)

Figure 15: Haemoglobin interference, examined using red blood cells
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Haemoglobin interference (Hb source = Hb calibrator)

Figure 16: Haemoglobin interference, examined using Hb calibrator
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Section 4
3.2.5 Comparisons between AU40Q chemistry analyzer and Camspec M55Q
spectrophotometer
3.2.5.1 Serum based comparisons
Samples in a range of 40 to 500 nmol/1 bilirubin were made up from a patient serum pool
and were run on both AU400 and on Camspec M550.
AU400 Result

Camspec

(nmol/l)

NBA (AU)

23.58

0.0013

57.41

0.0014

81.48

0.0018

109.27

0.0021

121.19

0.0026

118.54

0.0036

155.63

0.0041

163.57

0.0041

160.92

0.0052

202.04

0.0047

229.25

0.0058

231.97

0.0061

249.66

0.0061

286.4

0.0068

291.8

0.0074
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AU400 Result

Camspec

(nmol/1)

NBA (AU)

305.88

0.0078

325.0

0.0083

342.65

0.0091

369.12

0.0091

377.94

0.0105

403.36

0.0107

436.97

0.0119

460.50

0.0117

367.65

0.0144

I'able 6; Comparison of serum based test samples analysed by AU400 and by Camspec M550

Samples with a bilirubin value of 286.4nmol/l and lower, which were equivalent to Net
AU of 0.0068 and lower, gave an interpretative comment of “No significant bilirubin and
no oxyhaemoglobin present. No evidence to support subarachnoid haemorrhage”
Samples with a bilirubin value of 291.84 nmol/1 and higher, which were equivalent to Net
AU of 0.0074 and higher gave an interpretative comment of “Increased CSF bilirubin
with oxyhaemoglobin present. Consistent with subarachnoid haemorrhage”.
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3.2.5.2 CSF based comparisons
Samples in a range of 135 to 475 nmol/1 bilirubin were made up by spiking a patient CSF pool
with bilirubin values obtained from a diluted patient pool of serum. Samples were run on both
AU400 and on Camspec M550.

AU400 Result

Camspec

(nmoI/1)

NBA (AU)

141.06

0.0021

152.98

0.0026

190.06

0.0033

195.36

0.0045

204.76

0.0045

252.38

0.0055

253.74

0.0061

291.84

0.0073

290.48

0.0076

319.12

0.0084

351.47

0.0091

358.83

0.0096

377.94

0.0086

398.53

0.0121

410.08

0.0125

443.70

0.0134

453.78

0.0145

475.63

0.0154

Table 7: Comparison of CSF based test samples analysed by AU400 and by Camspec M550
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Samples with a bilirubin value of 253.74nmol/l and lower, which were equivalent to Net
AU of 0.0061 and lower, gave an interpretative comment of “No significant bilirubin and
no oxyhaemoglobin present. No evidence to support subarachnoid haemorrhage”
Samples with a bilirubin value of 291.84 nmol/1 and higher, which were equivalent to Net
AU of 0.0073 and higher gave an interpretative comment of “Increased CSF bilirubin
with oxyhaemoglobin present. Consistent with subarachnoid haemorrhage”.

Section 4
Discussion
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4.1 Discussion
Subarachnoid haemorrhage is a potentially fatal condition which may have an unclear
clinical presentation. A feature of this illness is the frequency of rebleeds, which often
result in more significant and more long-term damage than the original bleed. It is
essential therefore to quickly and correctly diagnose patients who have suffered from
SAH. The method of choice for diagnosis of SAH is computed tomography (CT) scans.
However, 2% of patients with SAH may present as negative on CT scanning. A need
exists for another method of confirmation of SAH in patients with clinical suspicion of
SAH but negative CT scans. This allows the identification of those positive for SAH
who will benefit from therapeutic interventions, and also reduces the referral of those
patients negative for SAH who would otherwise be subjected to dangerous and
complicated confirmatory procedures. Currently, the recommendation for these patients
is that they proceed to lumbar puncture and CSF is analysed for presence of bilirubin via
spectrophotometric scanning. Guidelines exist which provide recommendations for the
interpretation and reporting of spectrophotometric result"^.
Spectrophotometric analysis of CSF involves expensive equipment which is often only
available in larger centres.
Attempts have been made recently to develop automated methods for the detection of
bilirubin in CSF. The development of a robust automated method could allow for easy
detection of bilirubin in CSF and identification of patients with SAH. This could be
useful as a screening method to determine those samples that should be investigated by
spectrophotometry, or could replace spectrophotometry if the methods were found to be
sufficiently accurate.
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4.2 Optimisation of parameters
The method in use in Biochemistry Cork University Hospital for serum total bilirubin
measurement is the O’Leary ferricyanide method^^. Serum bilirubin levels are reported in
pmol/1. In an attempt to measure bilirubin at the much lower levels expected in the CSF
of SAH patients, it was attempted to adapt the parameters to allow for the detection of
bilirubin in nmol/1 levels. This was initially investigated by diluting a calibrator of known
bilirubin value to use as calibrator for the new parameters.
The calibrator used initially was the seronorm bilirubin calibrator. Sample volume was
increased to the maximum amount allowed by the instrumentation. This represented an
approximately 6 fold increase in sample volume. The assay was calibrated using a 7 point
calibration curve, made up by diluting the standard serum calibrator.
The absorbance changes were observed to be extremely small between values (Figure 3),
e.g.: Values from 0 to 100 nmol/1 gave absorbance differences of between 0.0000 and
0.0005. These very small changes in absorbance may result in an imprecise assay.
Accuracy was tested using QC material Triad 2 and Triad 3, diluted to give values
between the ranges of 0 to 1000 nmol/1. Values obtained using these parameters were
well below expected values and also showed no differentiation between values at the
lower end of the range (Figure 4). As the instrumentation does not permit further
increasing the sample volume, the amount of reagent used in the assay was decreased
several times since this is present in excess, in a bid to increase the sensitivity of the
assay. Particular attention was paid to the lower range of the assay, as an expected normal
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range for CSF bilirubin had been quoted in the literature as ~30 - 150 nmol/1, with an
expected mean of 90 nmol/1
Accuracy was tested using both calibrator and QC samples appropriately diluted.
To eliminate the possibility that poor results obtained may have been due to the effect of
the matrix tested, more than one test material was used i.e.: calibrator material, QC
material and a patient serum pool. QC samples were made up across an extended range.
Although the assay seemed to improve towards the upper half of the range 0 to 1000
nmol/1, they compared very poorly at low levels (Figure 8). This may be due to the very
small changes in absorbance in the calibration curve at these low levels. Both calibrator
and QC material were being used outside manufacturer’s recommendations. There was
some concern that the fact that these materials were greatly diluted may have led to their
poor performance, particularly at the lower levels. Therefore, a patient pool of serum was
obtained with a known total bilirubin value. This was diluted to give appropriate values
and assayed. The initial examination of parameters using patient pool for test samples
showed a somewhat improved performance compared to QC material (Figure 9). Lower
levels were well detected. Absorbance changes for these samples were larger than those
for the calibration curve, even at low levels, which may account for the improved
performance. However, some random errors were noted, these again being most notable
around the range which would be expected to be of clinical interest, i.e.: values between
100 and 200 nmol/P^. To improve readings at this low level, the calibration curve range
was reduced from a 0 to 1000 nmol/1 range to a 0 to 300 nmol/1 range. Test samples
created from both calibrator material and from a patient pool were run with the new curve
(Figure 10 and Figure 11). As can be seen from Figure 10 and Figure 11, the assay still
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appears imprecise at lower levels, with no discernable difference between some levels.
Again, the absorbance changes between values of the calibration curve were very small.
Precision checks were run at three levels and identified significant imprecision. Using
calibrator material, three values were made up of 50 nmol/1, 150 nmol/1 and 450 nmol/1
bilirubin for the inter run precision check. These gave CV’s of 55%, 11% and 4.2%
respectively. Precision of an assay should perform well across the entire range,
particularly at upper and lower ranges. An acceptable CV for within run precision should
be <10%. Although these parameters perform well at higher values, with CV of 4% for
450 nmol/1, a CV of 55% at the lower level of 50 nmol/1 demonstrates how imprecise the
assay is. This is further confirmed by the results of the intra run precision studies, which
gave CV’s of 84%, 32% and 37% respectively for values of 50 nmol/1, 150 ninol/1 and
380nmol/l. The results of the precision studies for these assay parameters clearly show
that they are unsuited to use as a routine assay in a clinical setting.
Other automated methods have been investigated for CSF bilirubin analysis and all of
these methods obtained good results by increasing sample volume alone. The modified
.laffe method on an Abbott Aeroset analyser was found to have precision of 11% and 200
nmol/1 and 7% at 400 nmol/P^. It was decided, therefore, to investigate the assay again,
this time using a different calibrator.
The original calibrator, the seronorm bilirubin calibrator, was chosen as it is a calibrator
in use in Biochemistry CUH specifically for bilirubin analysis, due to its stability over
several days. However, the absorbance changes observed with this diluted calibrator were
extremely small, which could account for the lack of precision of the assay. Therefore,
another calibrator was chosen, the Olympus system master calibrator. This calibrator is
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made up fresh on a daily basis in the laboratory and was diluted to the same values as the
seronorm ealibrator. Assay parameters were changed with the sample volume set to the
maximum allowable (50pl), and reagent volume was also set to half the volumes for
serum bilirubin detection (Reagent 1 = 25 pi in 100 pi diluent, Reagent 2 = 25 pi in 0 pi
diluent). This represented approximately a 12 fold increase in sample volume when
compared to parameters for the serum bilirubin assay. Absorbance values observed with
these parameters were twice those observed with the seronorm calibrator (Figure 12).
An investigation of a range from 0 to 300 nmol/1, using a patient pool of serum for test
samples, compared well from 70 nmol/1 to 300nmol/l (Figure 13). The fall off in values
towards the lower end may be due to the sensitivity of the assay at the lower end. On the
basis of this work, the parameters chosen for the measurement of CSF bilirubin were
Sample:
Reagents:

Volume

50

R1 Volume

25

R2 Volume
Wavelength:

Primary

Method:

25
480

n\

Dilution
Dilution

100

Dilution]

o

Secondary

ul

600

FN12

Measuring Point 1 (secs): First

Last

27

Measuring Point 2(secs): First

Last

10

The calibrator chosen for the assay was the Olympus system master calibrator.
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Any newly designed assay must meet a number of criteria prior to being introduced into a
routine laboratory for clinical use. Validation should include
•

Precision

•

Sensitivity

•

Linearity

The potential of interfering substances must also be investigated. Other factors for
consideration include cost of assay and ease of use. These will be considered in the
following sections.

4.3 Assay validation
Precision
Precision is the measure of the ability of an analytical method to produce the same value
from replicate measurements of the same sample.
Both inter run precision and intra run precision studies were performed.
FT)r inter run precision 20 replicates of three values were run and the data was analysed.
The values chosen represented a range which may be of clinical relevance. CVs of 1 1%,
8% and 4% were obtained for values of 50nmol/l, lOOnmol/1 and 200nmol/l bilirubin
respectively (Table 3). These are acceptable CV’s for an assay intended for routine use. A
CV of 8% at a range of 1 OOnmol/1 represents good performance by the assay.
With a mean of ~90nmol/l quoted in the literature for normal CSF bilirubin levels, it can
be concluded that the assay is extremely precise at the range of clinical interest. The
values determined to be of interest for this assay were found to be values in the range of
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290nmol/l. This will be shown in section 4.5 of the discussion. The CV at this range is
<5% which is ideal for an assay in use in a clinical setting.
Intra run precision was assessed over a period of >1 month (Table 4). Test values of
155nrnol/l (representing a normal CSF bilirubin) and 459 nmol/1 (representing a high
bilirubin value) were created by dilution of a patient pool. 50 replicates were assayed and
the data analysed. These values were also used as internal QC for the assay during the
course of later experiments. A CV of 13% was obtained for 155nmol/l and a CV of 11%
was obtained for 450nmol/l. This again represents acceptable assay performance.
The values used for intra run precision were also used as internal QC. This was due to
concerns about diluting regular QC material as it was shown to perform very poorly at
low levels. The internal QC used, therefore, gave a mean of 138 nmol/1 with CV of 13%
for the low level, and 423 nmol/1 with CV of 11% for the high level.

Limit of Detection (LOD)
The limit of detection of an assay, or its sensitivity, is the lowest amount that can be
measured that is distinguishable from zero. This was investigated using both distilled
water and saline. 20 replicated of each were analysed for bilirubin. The limit of detection
was defined as the mean of the results + 2S.D (Table 5).
The LOD for distilled water was determined to be 43.2 nmol/1.
The LOD for saline was determined to be 42.5 nmol/1.
These results are comparable, as would be expected. The sensitivity of the assay,
therefore, may be set at 45nmol/l for use in the routine laboratory setting.
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The inter run precision studies gave %CV of 1 1% for 50nmol/l, so it can be concluded
that the assay performs well as values just above 45 nmol/l. This indicates that results at
this very low level can be reliably quantified. As a reference range for normal CSF
bilirubin has been quoted in the literature as 30-150 nmol/1^^, this assay can be concluded
to have acceptable sensitivity.

Linearity
The assay would be expected to be linear across a range representing the calibration
curve, in this case 0 to 300 nmol/l. Linearity studies were performed to verify this and
also to determine how far the linearity of the assay might extend. Using a patient pool of
serum with known bilirubin value, a stock solution of lOOOnmol/1 bilirubin was created.
This was diluted to give values of between 0 and 1000 nmol/l.
The data was plotted and statistical analysis was performed (Figure 14).
On visual inspection of the graph, the assay looks linear across the range. Deviations at
the lower end of the range may correspond to results below defined limit of detection of
45nmol/l. A slight increase at the upper range can be attributed to a fall off in linearity
above a certain range. From visual inspection it can be concluded that the assay is linear
up to 800 nmol/l.
The statistical analysis of the data gave a linear fit equation of y = 1.05x - 30.64
The y-intercept is the point where the regression line crosses the y-axis, that is, the value
for y where x equals zero. The y-intercept represents the constant systematic error or
constant bias and should be as close to zero as possible^’. A y-intercept of -30.64, as
obtained here, is very acceptable.
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I'he ideal value of the slope of the regression line is 1. The deviation of the slope of the
regression line can be used as an estimate of the proportional systematic error of the
testing system. A slope of 1.048, as here, is again very acceptable. Based on this
statistical data, the assay can be deemed linear across a range of 0 to 1000 nmol/1.

4.4 Haemoglobin interference
A significant number of CSF samples are blood-stained due to the sampling process.
Therefore, it is essential that the potential for oxyhaemoglobin interference in CSF
bilirubin measurement is investigated, in order to distinguish a genuinely high CSF
bilirubin from a traumatic tap. I'o examine this, haemoglobin obtained from RBCs was
added in increasing amounts to a sample of known bilirubin value. The results were
plotted as haemoglobin mg/1 vs. bilirubin nmol/1. As can be seen from Figure 15,
increasing amounts of haemoglobin interfered strongly with the assay. Even at very low
levels of Hb e.g.: 11 mg/1, surprisingly strong levels on interference are seen. As even
small amounts of bilirubin that may have remained in the haemoglobin stock solution
would interfere strongly with this assay, the experiments were repeated, this time using a
calibrator of haemglobin value 11.5g/l and total bilirubin Oumol/1. Again the results were
similar to those seen when using RBCs as Hb source (Figure 14).
This may indicate an overlapping absorbance range for haemoglobin and bilirubin. Other
methods in the literature have demonstrated no interference at levels <100mg/l which
would not correlate with results observed here

However, these are diazo based

bilirubin methods. Also the absorbance of bilirubin is read at a higher wavelength.
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548nm, which may account for the non-interference of oxyhaemoglobin in the
Jaffe/Abbot assay.
For the purposes of this projeet, on the basis of these results it is coneluded that
haemoglobin interferes strongly with the assay. As haemoglobin interference is a critical
consideration in this assay due to the importanee of distinguishing genuine bleeds from
traumatic taps, it may be neeessary to adjust the wavelength at whieh the bilirubin is read.
The current parameters of the assay entail reading bilirubin at a primary wavelength of
480nm, followed by a reading at a secondary wavelength of 600 nm. By increasing the
primary wavelength from 480 nm to 490nm or 500nm, it may be possible to move further
away from the wavelength at which oxyhaemoglobin is detected, thereby removing the
interference of the oxyhaemoglobin in the bilirubin assay. This should be further
investigated prior to introducing this assay into routine use.

4.5 Comparisons between Automated Method and Camspec M550
spectrophotometer
Initially, a comparison was done between the two methods using samples ereated from a
patient pool of serum. Direct comparison of the results of the two methods indicate that
values from the automated method of 286.4 nmol/1 and lower correspond to
speetrophotometric results of Net bilirubin AU of 0.0068. This results in an interpretative
comment of “No signifieant bilirubin and no oxyhaemoglobin present. No evidence to
support subaraehnoid haemorrhage”.
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Samples with a bilirubin value of 291.84 nmol/1 and higher by the automated method,
which were equivalent to Net AU of 0.0074 and higher gave an interpretative comment
of “Increased CSF bilirubin with oxyhaemoglobin present. Consistent with subarachnoid
haemorrhage”.
Based on these results, a cut off point of 286.4 nmol/1 could be set as a negative result.
This could be useful if the assay were to be used as a screening method to determine
which samples proceed to spectrophotometric scanning. This could lead to correct
identification of those patients who are negative for SAH, and could significantly reduce
the number of samples which would require the more labour-intensive and costly
spectrophotometric investigation. It would be important to favour sensitivity over
specificity if this assay were to be used as a screening method. It is essential that no cases
of SAH are missed, as the consequences of missing positive cases could be fatal for the
patient.
As the assay is based on CSF samples, it is important to assess the assay based on a CSF
matrix as well as a serum matrix. A pool of CSF samples w'as therefore created and
spiked with bilirubin, and comparison studies were run on these samples, to determine
how the two methods correlated. The bilirubin used was from a patient pool of serum.
This would introduce similar interference to the CSF matrix, as would be seen in the
direct serum comparison. A more accurate investigation should be carried out spiking the
CSF pool with pure bilirubin.
Samples with a bilirubin value of 253.74nmol/l and lower, which were equivalent to Net
AU of 0.0061 and lower gave an interpretive comment of “No significant bilirubin and
no oxyhaemoglobin present. No evidence to support subarachnoid haemorrhage”
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Samples with a bilirubin value of 291.84 nmol/1 and higher, which were equivalent to Net
AU of 0.0073 and higher gave an interpretive comment of “Increased CSF bilirubin with
oxyhaemoglobin present. Consistent with subarachnoid haemorrhage”.

To accurately compare this automated method to the spectrophotometric method, a
prospective clinical study of the diagnostic accuracy should be performed, using
spectrophotometry as the reference method. The greatest difficulty in this lies in the
collection of adequate numbers of CSF samples. Currently, in Cork University Hospital,
only those patients who have negative CT scans have CSF samples referred to
Biochemistry for spectrophotometric scanning. To perform a prospective clinical study,
ethical approval would have to be sought to obtain samples from all suspected SAH
patients. It may be difficult to obtain ethical approval due to the invasive procedure
required to obtain the CSF sample.

Section 5
Conclusion
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Conclusion

The aim of this project was to develop an automated method for CSF bilirubin
measurement, to aid in the diagnosis of subarachnoid haemorrhage.
The method in use in Biochemistry CUH for serum total bilirubin measurement is the
O’Leary ferricyanide bilirubin method on an automated Olympus chemistry analyser.
The method was adapted by changing the instrument parameters to represent a 12 fold
increase in sample volume when compared to the serum method. The assay was
validated and proved to be precise, linear and have a limit of detection of 45 nmol/1.
Haemoglobin was found to significantly interfere with the assay.

Comparison of the automated method to the recommended spectrophotometric method
gave similar cut off points of approx 286nmol/l for serum and approx 253 nmol/1 for CSF
as values which give a negative result. However, these were tested using samples
containing a serum matrix which may cause interference. The assay should be further
investigated using a pure CSF matrix.

In conclusion, this method offers promise as a potential screening method for those
patients who present with clinical suspicion of SAH, but have negative CT scans.
The method is robust, easy to use, requires less CSF sample than spectrophometric
scanning and is a relatively inexpensive assay.
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Future direction

Further attempts should be made to eliminate haemoglobin interference, possibly by
adjusting the wavelength at which bilirubin is read, in order to move it further away from
the wavelength at which oxyhaemoglobin is read.

Although this method offers hope as either a screening test, or even to replace the
spectrophotometric method, it is essential to establish cutoff points and reference ranges
for individual laboratories. To enable this, a prospective validation using patient samples
should be carried out to determine diagnostic accuracy of the method. All patients
presenting with clinical suspicion of SAH should have CSF samples taken for bilirubin
analysis. All samples coming to the laboratory for CSF bilirubin analysis should be
analysed by both the spectrophotometric method and the automated method. In positive
cases by spectrophometry, a corrected NBA should be calculated using CSF and serum
protein, and serum bilirubin. This correction prevents false positive results due to high
serum bilirubin levels e.g.: as seen in hyperbilirubinaemia.
Receiver operating characteristics (ROC) curve analysis should be performed on results
to determine the ability of CSF bilirubin to predict patients with increased NBA, and to
exclude those patients with negative scans.
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